Drugs / AZD7798
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06432764 | Oct 2024 → Mar 2026 | Crohn disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06053424 | Sep 2023 → Oct 2024 | Crohn disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05452304 | Jul 2022 → Nov 2024 | Crohn disease | AstraZeneca | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06681324 | Dec 2024 → Aug 2026 overdue | Crohn disease | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06450197 | Aug 2024 → Apr 2026 overdue | Crohn disease | AstraZeneca | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD7798 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06053424 ↗ |
| Route | Intravenous | “IV infusion of AZD7798” NCT06053424 ↗ |